A7.10 Results of abatacept treatment in patients with different duration of rheumatoid arthritis
| Autor: | Y. Sigidin, Svetlana Glukhova, E. Aronova, D.E. Karateev, E. Luchihina, Nasonov El, Galina Lukina, M. Kanonirova |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty business.industry Abatacept Immunology medicine.disease Connective tissue disease General Biochemistry Genetics and Molecular Biology Surgery Clinical trial Rheumatology Tolerability Internal medicine Rheumatoid arthritis medicine Immunology and Allergy In patient skin and connective tissue diseases Adverse effect business Moderate Response medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 75:A59.2-A60 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Background and objectives Efficacy and tolerability of abatacept (ABA) is confirmed in randomised clinical trials. There isn’t enough data about results of ABA treatment in patients (pts) with different duration of rheumatoid arthritis (RA). Objectives To analyse efficacy and safety of ABA treatment in pts with early (ERA) and long-standing (LS) RA. Materials and methods Eighty patients with active RA were divided in two groups, the first one, less than three years duration (ERA - 51%) and the second one, more than three years duration (LS RA – 49%). Most of them were women, age 49 ± 13.5 years, with a high disease activity (DAS28=5.25 ± 1.15), RF-positive (75,7%) and ACPA-positive (75%). Disease activity was measured by DAS28, functional status – by HAQ-DI. Results were assessed every 12 weeks by EULAR criteria. Results Pts had high disease activity by DAS28 (ERA DAS28–5.1 ± 0.9, LS RA - 5,3) and mild disability by HAQ-DI (ERA - 1.3 ± 0.6, LS RA - 1.6 ± 0.9) before treatment. Good and moderate response by EULAR criteria was achieved in 80% in the group of ERA and in 67% of pts with LS RA (p Conclusion ABA has shown significant improvement in reduction of disease activity in pts with an inadequate response to previous therapy. There was no significant difference in achieving good EULAR response between pts with early and LS RA. However, pts in ERA group had significant improvement of HAQ-DI comparing with LS RA group. ABA has good safety profile, adverse events were registered only in 20% of pts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|